Halifax, Nova ScotiaSixth Wave Innovations Inc. (CSE:SIXW) (OTCQB:SIXWF) (FSE:AHUH) (‘Sixth Wave’, ‘SIXW’ or the ‘Company’) is pleased to announce that its rollout plan to launch customers of the Affinity system (‘ System’) runs well on the go.

Sixth Wave delivered a Discovery Affinity System Retro/Advanced Extraction Systems Inc. (‘AESI’) and conducted functional training on the system. The companies expect to have this system operational in the first week of August when Sixth Wave is able to bring its portable analysis system to the facility. Retro uses a supercritical CO2 to extract cannabinoids to create a variety of products, with a focus on craft formulations and vape products. Consistent with previous announcements, Sixth Wave and AESI will be able to perform a variety of functions with this system, in addition to processing for retro. This discovery system will be used to train AESI personnel on the Affinity system to prepare them to take on the sales, installation and support of the Affinity system as part of the exclusive license agreement. Schedules permitting, AESI and Sixth Wave will begin inviting prospects who have expressed interest in the Affinity System to Retro/AESI once the Discovery System is fully configured.

Sixth Wave will also be attending quantum laboratory in New Mexicoto meet with the owner Nicholas Montoya who signed a letter of intent earlier this year to deliver an Affinity system (“System”). The focus of the planned visit 15th of August is to be checked quantum laboratory Progressing work on site and discussing installation plans, including delivery of a Discovery-sized Affinity system to perform configuration testing on the Quantum extracts prior to production.

In addition, Sixth Wave continued on-site technical assessments and business development activities Michigan the week of June 28th. Link: The projects took place at an award-winning recreational and medicinal cannabis supplier that is being planned Michigan’s largest and leading supply center chain in the Big lakes as a multi-state operation. The team was extremely excited about Affinity nanotechnology and the operational benefits it offers for improved product extraction and purification. The technical assessment was particularly helpful to the onsite extraction and production experts who were briefed on the upcoming work/installation plan. Sixth Wave expects to return in the next few weeks for configuration testing of its discovery-sized Affinity system and handheld analyzers. These tests will confirm the performance attributes of the Affinity system with THC acid forms (non-decarboxylated) prior to delivery to the production system.

“We are pleased with the major advances, particularly at AESI, as they are critical to expanding our international resources in the current rollout of our Affinity systems. The early integration of the AESI engineers, sales and support team is going smoothly while we continue to work on servicing the existing customers. Our discussions with AESI and Retro once again confirm that the cleanability and operating parameters of the Affinity system will be valuable to the industry. Additional outreach from Sixth Wave in recent weeks has added three new potential clients to the list in both South and Australia North America. AESI will begin to ramp up sales efforts with their existing customer base and others over the coming weeks.’ notices dr. Jon GluckmanPresident and CEO of Sixth Wave.

About the sixth wave

Sixth Wave is a nanotechnology company with patented technologies focused on the extraction and detection of target substances at the molecular level using highly specialized molecularly imprinted polymers (MIPs). The Company is in the process of commercializing its Affinity cannabinoid purification system, as well as IXOS, a line of extraction polymers for the gold mining industry. The Company is also in the development phase of a rapid diagnostic test for viruses called Accelerated MIPs (AMIPS).

Sixth Wave can design, develop and market MIP solutions for a wide range of industries. The Company is focused on nanotechnology architectures highly relevant to the detection and separation of viruses, biogenic amines and other pathogens for which the Company has products in various stages of development.


Telephone: (801) 582-0559

Email: [email protected]


This press release contains certain statements that may be deemed “forward-looking statements”, including possible statements regarding the planned use of the proceeds and performance of the IXOS, Affinity and AMIPs technologies. All statements in this press release, other than statements of historical fact, that address future events or developments that the Company expects are forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual events or developments may differ materially from those projected in the forward-looking statements. Such forward-looking statements inherently involve known and unknown risks and uncertainties that could cause the Company’s actual performance and financial results in future periods to differ materially from the projections of future performance or results expressed or implied by such forward-looking statements. In particular, the successful development and commercialization of the IXOS, Affinity or AMIPs technologies is subject to the risk of not proving successful, uncertainty of medical product development, uncertainty of timing or availability of required regulatory approvals, lack of track record of development of products for specific applications and the need for additional capital to carry out product development activities. The value of any products eventually developed could be adversely affected if patents are not granted. The company has not yet applied to any regulatory agency for regulatory approval for the use of this product.

Leave a Comment